<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00862862</url>
  </required_header>
  <id_info>
    <org_study_id>002-09-FB</org_study_id>
    <nct_id>NCT00862862</nct_id>
  </id_info>
  <brief_title>Evaluation of Vancomycin Treatment of Infections Due to Staphylococcus Aureus</brief_title>
  <official_title>Evaluation of Pharmacodynamic Target Attainment With Vancomycin Treatment of Infections Due to Staphylococcus Aureus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: The objective of the study is to evaluate the ability of current vancomycin dosing&#xD;
      strategies to attain the pharmacodynamic target of an area under the curve (AUC) to minimum&#xD;
      inhibitory concentration (MIC) ratio greater than 400:1 for patients with a suspected or&#xD;
      documented Staphylococcus aureus infection.&#xD;
&#xD;
      Primary Outcome: The primary outcome is the percentage of vancomycin dosing regimens that&#xD;
      achieve AUC:MIC ratio &gt; 400 on the first occurrence of vancomycin use in patients with a&#xD;
      suspected or documented S. aureus infection at The Nebraska Medical Center.&#xD;
&#xD;
      Secondary Outcomes:&#xD;
&#xD;
        1. To assess the probability that vancomycin AUC:MIC ratios obtained from The Nebraska&#xD;
           Medical Center patients exceed a therapeutic threshold using S. aureus MICs from&#xD;
           isolates obtained from The Nebraska Medical Center.&#xD;
&#xD;
        2. Using MIC data from the TRUST Study database (large national surveillance database) and&#xD;
           the vancomycin AUC data obtained from TNMC patients, perform a Monte Carlo analysis that&#xD;
           will assess the probability of achieving a therapeutic vancomycin threshold with a large&#xD;
           number of isolates.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: This is a prospective cohort study with a retrospective chart review component.&#xD;
&#xD;
      Inclusion and Exclusion Criteria: Inpatients of The Nebraska Medical Center will be included&#xD;
      if they are 19 years of age or older, prescribed intravenous vancomycin therapy with a dosing&#xD;
      interval of 24 hours or less, and therapy is continued for at least 3 doses or five half&#xD;
      lives. Exclusion criteria consists of an estimated creatinine clearance less than 30 ml/min,&#xD;
      concurrent use of dialysis, and pregnancy.&#xD;
&#xD;
      Interventions: For the prospective component eligible patients will be consented and&#xD;
      enrolled. A vancomycin trough level will be determined as normal standard of care thirty&#xD;
      minutes prior to the appropriate vancomycin dose, followed by a vancomycin peak level one&#xD;
      hour after the end of the infusion. Serum concentration time data will then be used to&#xD;
      calculate an AUC. The retrospective component of the study will involve a chart review of&#xD;
      patients treated with vancomycin in which a serum trough and peak level was obtained and&#xD;
      calculation of the AUC as described.&#xD;
&#xD;
      Evaluations: Serum concentration time data will be used to calculate an AUC for each patient&#xD;
      enrolled in the study and from all charts reviewed that meet criteria. MIC data will be&#xD;
      determined for Staphylococcus aureus isolates obtained from The Nebraska Medical Center. The&#xD;
      two sets of data will then be used to calculate an AUC:MIC ratio. The AUC:MIC data will be&#xD;
      compared to the goal ratio of greater than 400. Additionally, using the AUC data from our&#xD;
      patients and the MICs derived from a large national surveillance data base, a Monte Carlo&#xD;
      analysis will be completed to determine the probability of achieving therapeutic ratios.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of enrollment&#xD;
  </why_stopped>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome is the percentage of vancomycin dosing regimens that achieve AUC:MIC ratio &gt; 400 on the first occurrence of vancomycin use in patients with a suspected or documented S. aureus infection at The Nebraska Medical Center.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Using MIC data from the TRUST Study database and the vancomycin AUC data obtained from TNMC patients, perform a Monte Carlo analysis that will assess the probability of achieving a therapeutic vancomycin threshold with a large number of isolates</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">250</enrollment>
  <condition>Staphylococcus Aureus</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with suspected or documentd staphylcoccus aureus infection and prescribed&#xD;
        vancomycin&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  19 years of age or older&#xD;
&#xD;
          -  Admitted to an inpatient care unit at The Nebraska Medical Center&#xD;
&#xD;
          -  Prescribed intravenous vancomycin therapy with a dosing interval of 24 hours or less&#xD;
&#xD;
          -  Vancomycin therapy that lasts for at least 3 doses or 5 half-lives as scheduled with&#xD;
             no dosage changes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Estimated creatinine clearance (CrCl) less than 30 ml/min using the Cockroft-Gault&#xD;
             equation (in patients over the age of 65 a SCr of 1.0 mg/dL will be assumed for all&#xD;
             patients with a reported SCr less than 1.0 mg/dL). Ideal body weight will be used for&#xD;
             the Cockroft-Gault equation unless the actual body weight is less than the ideal body&#xD;
             weight.&#xD;
&#xD;
          -  Patients requiring any form of dialysis&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith M Olsen, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>March 13, 2009</study_first_submitted>
  <study_first_submitted_qc>March 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2009</study_first_posted>
  <last_update_submitted>May 27, 2015</last_update_submitted>
  <last_update_submitted_qc>May 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Keith Olsen, PharmD, FCCP, FCCM</investigator_full_name>
    <investigator_title>Professor and Chair</investigator_title>
  </responsible_party>
  <keyword>infection</keyword>
  <keyword>staphylococcus aureus</keyword>
  <keyword>vancomycin</keyword>
  <keyword>pharmacodynammics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

